Roche trials could provide new ovarian cancer treatment

People looking to get into pharmaceutical sales jobs could soon be selling a new ovarian cancer therapy which has been successful in recent studies.

Pharmaceutical giant Roche completed a study that showed the combination of Avastin and chemotherapy followed by the continued use of the drug, also known as bevacizumab, increased the time women lived without the disease worsening.

Hal Barron, executive vice-president Global Development and chief medical officer for Roche, said that the study is part of the company's continued commitment to studying ovarian cancer.

"With few advances in ovarian cancer and a need to improve outcomes for women with this disease, it is encouraging that a second phase III study showed that Avastin in combination with chemotherapy followed by the continued use of Avastin alone helped women live longer," he added.

Roche recently released an overview of the new medicines in early-stage studies that were presented at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

As a specialist pharmaceutical sales recruitment agency, Aaron Wallis recruit for many of the UK's leading pharma companies. For pharmaceutical sales employers Aaron Wallis offer a comprehensive sales recruitment service that includes skills testing, psychometric profiling and a 52-week rebate scheme.

Posted by Nikki Barrister

Filed: 06-07-2010